Currently out of the existing stock ratings of Geoff Meacham, 181 are a HOLD (35.15%), 300 are a BUY (58.25%), 34 are a SELL (6.6%).

Geoff Meacham

Work Performance Price Targets & Ratings Chart

Analyst Geoff Meacham, currently employed at BAML, carries an average stock price target met ratio of 60.3% that have a potential upside of 29.68% achieved within 260 days. Previously, Geoff Meacham worked at JPMORGAN, CITI, BARCLAYS.

Geoff Meacham’s has documented 1,012 price targets and ratings displayed on 75 stocks. The coverage is on Healthcare, Technology, Industrials, Basic Materials sectors.

Most recent stock forecast was given on APGE, Apogee Therapeutics, Common Stock at 23-Jun-2026.

Wall Street Analyst Geoff Meacham

Analyst best performing recommendations are on TYRA (TYRA BIOSCIENCES).
The best stock recommendation documented was for TYRA (TYRA BIOSCIENCES) at 10/11/2021. The price target of $22 was fulfilled within 11 days with a profit of $6.6 (42.86%) receiving and performance score of 38.96.

Average potential price target upside

of $291.61 (75.52%) on BTAI (BIOXCEL THERAPEUTICS).
of $91.07 (22.04%) on LLY (ELI LILLY AND COMPANY).
of $85.96 (16.1%) on REGN (REGENERON PHARMACEUTICALS).

ALXN Alexion Pharmaceuticals AMGN Amgen BIIB Biogen BMRN Biomarin Pharmaceutical BMY Bristol-Myers Squibb Company BTAI BioXcel Therapeutics CMPI Checkmate Pharmaceuticals CVAC CureVac NV GILD Gilead Sciences IIVI II-VI INCY yte INO Inovio Pharmaceuticals JNJ Johnson & Johnson LLY Eli Lilly and Company MRK Merck mpany MRNA Moderna PFE Pfizer REGN Regeneron Pharmaceuticals VRTX Vertex Pharmaceuticals KNSA Kiniksa Pharmaceuticals Ltd PMVP Pmv Pharmaceuticals PTCT PTC Therapeutics SGEN Seagen ABBV AbbVie ARAV Aravive CELG Celgene KYMR Kymera Therapeutics NBIX Neurocrine Biosciences ABOS Acumen Pharmaceuticals UTHR United Therapeutics VAXX Vaxxinity XLRN Acceleron Pharma ALNY Alnylam Pharmaceuticals ACHN Achillion Pharmaceuticals BBIO BridgeBio Pharma CMRX Chimerix CRBU Caribou Biosciences CRSP Crispr Therapeutics AG GRPH Graphite Bio ICPT Intercept Pharmaceuticals IPSC Century Therapeutics MYOV Myovant Sciences Ltd OMER Omeros PRTA Prothena plc RPRX Royalty Pharma Plc RTRX Travere Therapeutics TYRA Tyra Biosciences IGMS IGM Biosciences RANI Rani Therapeutics Holdings VIR Vir Biotechnology LIAN LianBio ADR AMLX Amylyx Pharmaceuticals JANX Janux Therapeutics RNA Avidity Biosciences LYEL Lyell Immunopharma NMRA Neumora Therapeutics BNTX BioNTech SE GOSS Gossamer Bio RGNX Regenxbio PTGX Protagonist Therapeutics APGE Apogee Therapeutics, Common Stock ACH Aluminum Corp of China Ltd ADR ACLX Arcellx AL Air Lease BHC Bausch Health Companies BHVN Biohaven Pharmaceutical Holding Co Ltd CMP Compass Minerals International CV DBVT DBV Technologies GNFT Genfit NAMS NewAmsterdam Pharma Company N.V. Ordinary Shares NVAX Novavax SG Sweetgreen SRRK Scholar Rock Holding Corp ESPR Esperion Therapeutics

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Hartaj Singh (OPPENHEIMER)